Sentences with phrase «on drug companies»

[This «broader environment» would, surprise, surprise, be an office within the FDA — you know, the government — with binding authority on the drug companies.

Part of Obamacare's funding comes from taxes on drug companies.

The budget includes taxes on «windfall» profits of health insurance companies that have benefitted from the December tax law and a surcharge on drug companies that manufacture opioids.

I think people in the U.S. wait on drug companies to tell us when something is okay to take... where were they when our ancestors were already doing this?

Concerns that a Hillary Clinton administration would impose greater price regulation on drug companies had put a damper on pharmaceutical stocks for more than a year.

And he's been taking on drug companies since 2011.

But today, his fund, which once grew as large as $ 36 billion under management in 2011, has dwindled to $ 10 billion, following double - digit losses on wrong - footed bets on drug companies in 2016.

Goldman Sachs (NYSE: GS) raised its rating on that drug company to buy from neutral and named it to its conviction list of favorite stocks.

His work focused on drug company payments to a psychiatrist at the University of Cincinnati, another at Stanford University, and Charles Nemeroff, then with Emory University — causing much chaos and agitation among researchers — and changes in numerous academic conflict - of - interest policies.

Moreover, given the stress on drug company profits, the show might have taken a minute to point out that both simvastatin (Zocor) and atorvastatin (Lipitor) are now off - patent.

Not exact matches

Instead of focusing on developing a blockbuster drug only to have it fail in trials, Tehrani's company would concentrate on the process of innovation.

May 1 - Regeneron Pharmaceuticals and Sanofi will cut the net price of their expensive cholesterol drug for Express Scripts customers in exchange for greater patient access, with some savings to be shared with consumers, the companies said on Tuesday.

Cramer was also burned on Pfizer's aborted takeover bid for drug company Allergan, which had an overseas taxation rate that would allow the company to pay lower taxes than if it were based in the U.S.

One biotech firm, Ossianix, is already hard at work developing a VNAR - based drug - delivery system, in collaboration with the global pharmaceutical company Lundbeck, which focuses on drugs for brain disorders.

The facility where the investigators had assembled that morning, brandishing an Administrative Inspection Warrant, was a distribution center operated by one of America's largest public companies, the giant drug wholesaler McKesson (mck), which ranks No. 5 on this year's Fortune 500.

The $ 1.1 billion Alphabet - backed Silicon Valley unicorn 23andMe just pulled off a milestone feat: On Thursday, the Food and Drug Administration (FDA) said the company could sell its genetic tests and accompanying health risk reports for ten different diseases directly to consumers.

Valeant's largest shareholder, billionaire and hedge funder John Paulson, has gained a seat on the drug maker's board, sending the beleaguered company's stock spiking more than 6 % in Monday trading (although it's still hovering at around the $ 13 mark).

The 32 - year - old Ramaswamy has been able to sway a slew of biopharma vets to lead his companies and take a chance on his audacious, risky approach to drug development.

The Hong Kong - listed company has two blockbuster drugs on its roster — anlotinib for lung cancer and tenofovir for hepatitis B — and a few blockbuster generics aiming for approval before 2021.

On average, the 30 large and small pharmaceutical and biotech companies IDEA Pharma examined got just 11 % of their 2017 revenue from drugs developed within the past five years, says Mike Rea, the firm's CEO and one of the most insightful people I've met — no exaggeration — when it comes to pinpointing innovation choke points in the drug industry.

The Food and Drug Administration delivered a boon to U.S. drug giant Johnson & Johnson on Thursday, approving the company's psoriasis treatment Tremfya (a psoriasis drug that analysts say could wring in billions of dollars in annual salDrug Administration delivered a boon to U.S. drug giant Johnson & Johnson on Thursday, approving the company's psoriasis treatment Tremfya (a psoriasis drug that analysts say could wring in billions of dollars in annual saldrug giant Johnson & Johnson on Thursday, approving the company's psoriasis treatment Tremfya (a psoriasis drug that analysts say could wring in billions of dollars in annual saldrug that analysts say could wring in billions of dollars in annual sales).

Swiss drug giant Novartis has struck a deal to acquire France's Advanced Accelerator Applications (AAA) for $ 3.9 billion, or a nearly 50 % premium on the company's closing share price before knowledge of the deal became public.

The incentive — or threat — is that if drug companies fail to pay rebates, they might not win spots on a list of preferred medications that the PBMs maintain.

That provision would have allowed approved drugs that win additional FDA clearances to treat rare disorders — i.e., those that affect 200,000 or fewer Americans — extended market exclusivity in the hopes that biopharma companies would be more compelled to invest in difficult - to - treat spaces that involve costly follow - on clinical trials.

Valeant has been at the center of a political firestorm over prescription medication costs and pharmaceutical companies, which depend more on acquiring or licensing existing therapies (and then raising their prices) rather than fueling R&D into new drugs.

These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so - called «Paragraph IV» litigation and other patent litigation, related to any of our products or products using our proprietary technologies, which may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence of efficacy and adequacy of bridging to buprenorphine; clinical development activities may not be completed on time or at all; the results of our clinical development activities may not be positive, or predictive of real - world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading «Risk Factors» in the company's most recent Annual Report on Form 10 - K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website at www.sec.gov.

On the surface, Papa seems to have gotten an extraordinarily generous deal to turn around the beleaguered drug company: Not only is his salary more than twice what it was when he was CEO of Perrigo (prgo), a company nearly three times as valuable as Valeant (vrx), it's also especially good considering Valeant's stock price has fallen nearly 67 % since he took over.

On Wednesday, hedge fund manager Bill Ackman, who recently joined Valeant's board, pledged to end the company's practice of aggressively hiking drug prices.

Activist hedge fund investor and recent Valeant Pharmaceuticals (vrx) board appointee Bill Ackman on Wednesday slammed the company's steep drug price hikes in testimony before the U.S. Senate Special Committee on Aging, going so far as to say the cost bumps «contributed to healthcare inflation and called into question the company's commitment to the patients it serves.»

Martin Shkreli, unaffectionately known as the «pharma bro» — and infamous for his decision to hike the list price of Daraprim, a drug used by HIV / AIDS and cancer patients to combat infections, by more than 5,000 % in 2015 under his former company Turing Pharmaceuticals — was convicted on three criminal securities fraud and conspiracy charges by a Brooklyn jury on Friday.

Over in the House of Representatives, Democrats have also been hot on the tail of pharmaceutical companies that have jacked up the prices of some of their drugs, though they've making less headway than their Senate bipartisan counterparts.

«And as long as that happens, your insurance company is not going to pay your bill if you take a drug and the pharmaceuticals are not going to develop the drugs because if nobody is going to pay for their use, why spend the money on that?»

One key differentiator is that these companies are testing with the Food and Drug Administration and making products for medical marijuana and MassRoots is focused on recreational marijuana users.

Prior to Sucampo, he served as Chief Scientific Officer of Ambrx Inc., a clinical - stage biopharmaceutical company focused on the development of antibody - drug conjugates (ADCs) that was acquired by a consortium led by Fosun Pharmaceutical Group in 2015.

On Wednesday, Swiss pharmaceutical giant Novartis made history as the first company to win Food and Drug Administration (FDA) approval for a groundbreaking new type of cancer treatment known as CAR - T.

But at the same time drug companies were increasing prices for many drugs, insurance plans have been going through their own transformation, leaving more families like the LePeres on the hook for far more of that cost.

The company is selling a thing (the kit) by saying it can provide «health reports on 254 diseases and conditions,» including categories such as «carrier status,» «health risks,» and «drug response,» and specifically as a «first step in prevention» that enables users to «take steps toward mitigating serious diseases» such as diabetes, coronary heart disease, and breast cancer...» Most of the uses «listed on your website, a list that has grown over time,» the FDA writes, «are medical device uses [for the] Personal Genome Service.»

But Sarepta CEO Ed Kaye played up the drug's initial sales during the J.P. Morgan Healthcare conference in San Francisco, sending the company's shares flying 21 % in Tuesday trading (they've fallen off a little on Wednesday).

Celgene's patents likely won't be challenged by its rivals anytime soon — its three main patents expire in the 2020s, by which point the company will have made a considerable amount of money on the drugs.

The company has responded with statements saying that it's not as dependent on drug price increases as critics have claimed; it has also pointed out that while attention has focused on changes in list prices for drugs, those prices don't reflect the actual cost for insurers, governments and other group purchasers, which typically receive discounts that aren't publicly disclosed.

The memory - eating disease, expected to afflict 15 million Americans by 2060 (and tens of millions more around the world as life expectancy increases), has no cure; a new drug for the condition hasn't been approved in well over a decade; initially promising experimental treatments seem to be failing with clockwork regularity; and there's not even a definitive consensus on what, exactly, biopharma companies should focus on while developing Alzheimer's medicines.

STAT reached out to the 15 biggest drug companies about the immigration ban; only Johnson & Johnson, Merck, and Novartis responded with statements — and they simply expressed support for affected employees, without taking a stance on Trump's action.

Cummings: The research has shown, first of all, that whenever [Congress] shine a light on prescription - drug companies with regard to price hikes automatically they have a tendency to slow down the rate of price hikes.

After a drug arrest (but no conviction) Parker quit the company but has still been involved on an informal basis.

Finally, on May 13, the company pleaded guilty to seven federal criminal counts of selling adulterated drugs and making false statements to the U.S. government.

Many drug company executives, including the CEOs of Pfizer and Allergan, were asked about the prospect of working with Amazon on their most recent quarterly earnings conference calls.

The hedge fund manager's investor call came on the heels of Valeant's announcement earlier Friday morning that it was «severing all ties» with Philidor Rx Services, the mail - order pharmacy whose relationship with the drug company had sparked the whole hullabaloo about potential wrongdoing.

The article described how an internal investigation conducted by a company executive, Dinesh Thakur, who went on to become a whistleblower, reported appalling deceit: Ranbaxy scientists substituted cheaper, lower - quality ingredients in place of better ingredients, manipulated test parameters, and even bought brand - name drugs and used them in place of their own generics to win FDA approval.

Stocks in the Anglo - American drug company Shire rose as much as 26 % on Wednesday, following news that Japan's Takeda Pharmaceutical might make an approach.

While several of the present CEOs responded optimistically to the meeting — praising the deregulation and tax reduction components in particular — and many of their companies» shares rose on hopes that Trump won't be as antagonistic toward drug makers as his recent comments that they're «getting away with murder» on prices would suggest, don't count on the wish list to come true.